Pomerantz LLP Investigates Braskem Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Should l Buy BAK?
Source: PRnewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud and other unlawful business practices by Braskem S.A., urging investors to contact attorneys to join the class action, highlighting serious concerns over corporate governance and transparency.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure, but this news led to a 14.71% drop in its ADR price, reflecting market worries about the company's financial health.
- Deteriorating Financial Performance: On March 26, 2026, Braskem reported widening losses and issued a going-concern warning for 2025, causing its ADR price to fall by 10.66%, indicating significant financial pressure on the company.
- Increased Legal Risks: As Pomerantz LLP's investigation progresses, Braskem faces heightened legal risks that could impact its future financing capabilities and market trust, exacerbating investor anxiety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAK
Wall Street analysts forecast BAK stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 3.690
Low
3.30
Averages
3.30
High
3.30
Current: 3.690
Low
3.30
Averages
3.30
High
3.30
About BAK
Braskem SA is a Brazil-based company primarily engaged in the plastic production. The Company operates in the first and second generations of the petrochemical industry and its activities are divided into three operational segments: Brazil; the United States and Europe; and Mexico. The Brazil segment is focused on the production of polyethylene (PE), polypropylene (PP), polyvinylchloride (PVC) and caustic soda, among others. The United States and Europe segment is responsible for the production, operations, and sales of polypropylene in the United States and Germany. The Mexico segment comprises production, operation, and sale of ethylene, high-density polyethylene (HDPE), and low-density polyethylene (LDPE).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Braskem Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud and other unlawful business practices by Braskem S.A., urging investors to contact attorneys to join the class action, highlighting serious concerns over corporate governance and transparency.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure, but this news led to a 14.71% drop in its ADR price, reflecting market worries about the company's financial health.
- Deteriorating Financial Performance: On March 26, 2026, Braskem reported widening losses and issued a going-concern warning for 2025, causing its ADR price to fall by 10.66%, indicating significant financial pressure on the company.
- Increased Legal Risks: As Pomerantz LLP's investigation progresses, Braskem faces heightened legal risks that could impact its future financing capabilities and market trust, exacerbating investor anxiety.
See More
Braskem Faces Securities Fraud Investigation by Pomerantz LLP
- Investigation Launched: Pomerantz LLP is investigating whether Braskem and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure; however, this news caused its ADR price to drop by 14.71%, reflecting market concerns about its financial health.
- Widening Financial Losses: On March 26, 2026, Braskem reported its fourth quarter and full year 2025 financial results, revealing widening losses and a going-concern warning, which led to a further 10.66% decline in ADR price, indicating the financial pressures the company is facing.
- Potential Legal Consequences: As the investigation unfolds, if Braskem and its executives are found to have engaged in misconduct, it could trigger class action lawsuits, further impacting the company's reputation and shareholder confidence.
See More
Braskem Unveils Sustainable Packaging Solutions at Interpack 2026
- Sustainable Material Innovation: At Interpack 2026, Braskem showcases I'm green™ bio-based polyethylene specifically designed for food-contact applications, marking the first sustainable sugarcane-derived plastics offered, aimed at meeting the growing demand for eco-friendly packaging and facilitating the transition to a low-carbon economy.
- New Healthcare Product: The newly introduced Medcol V7040 low-density polyethylene is specifically developed for the healthcare sector, meeting stringent pharmaceutical regulations while offering excellent flowability and temperature resistance, serving as a true drop-in solution to support sustainable medical packaging.
- Support for Circular Economy: Braskem's portfolio spans renewable to recycled materials, providing multiple solutions that enable brands to achieve sustainability goals while ensuring performance and supply reliability, thus promoting the realization of a circular plastic economy.
- Interactive Exhibition Highlights: At Interpack, Braskem will feature interactive displays and expert sessions to highlight its product innovations in the circular plastic economy, emphasizing their potential applications across food, healthcare, and personal care sectors.
See More
Braskem to Transfer Control to Shine I Fund
- Control Transfer Agreement: Braskem announced that Novonor and NSP Investimentos have signed an agreement to sell control of the company to private equity fund Shine I, managed by IG4 Capital, with completion expected within 30 days, indicating a significant shift in governance structure.
- Shareholders Agreement Upcoming: Within the next 30 days, Shine I and Petrobras are expected to sign a new shareholders' agreement governing Braskem's operations, further solidifying the new investor's control over the company.
- Petrobras Evaluation: Petrobras, which currently owns 47% of Braskem's voting shares and 36.1% of its total shares, is evaluating the terms of the transaction to decide on its waiver rights, which could impact the final outcome of the deal.
- Voting Shares Sale Details: The agreement details the court-supervised sale of approximately 50.1% of Braskem's voting shares and about 34.3% of its total shares, reflecting a significant adjustment in the shareholder structure that may influence future operational strategies and market performance.
See More
Braskem Faces Securities Fraud Investigation by Pomerantz LLP
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Braskem and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure; however, this news caused its ADR price to drop by 14.71%, indicating market concerns about its financial health.
- Deteriorating Financial Performance: On March 26, 2026, Braskem reported widening losses and issued a going-concern warning in its 2025 financial results, further undermining investor confidence.
- ADR Price Volatility: Following the financial report, Braskem's ADR price fell by 10.66% to $3.52 per ADR, reflecting a pessimistic outlook from the market regarding its future prospects.
See More
Braskem Reports Q4 Losses Nearly Doubling, Faces Material Uncertainty
- Deteriorating Financials: Braskem reported a Q4 net loss of 10.28 billion reais (approximately $1.96 billion), nearly doubling from 5.64 billion reais a year earlier, indicating significant challenges in financial management that could impact future financing capabilities.
- Revenue Decline: The company's Q4 net revenue fell by 7% to 16.1 billion reais, primarily due to tax writedowns, provisions related to the Alagoas salt mine incident, and currency effects, suggesting that while the core business remains intact, external factors have significantly pressured performance.
- Rising Debt: Braskem's adjusted net debt increased to $7.5 billion in Q4, with leverage surging to 14.74x, reflecting severe risks to its debt repayment capacity, potentially forcing the company to seek bankruptcy protection or pursue out-of-court restructuring in the coming months.
- Ongoing Governance Risks: Following multiple failed divestment attempts by controlling shareholder Novonor after Brazil's Carwash corruption scandal, Braskem faces ongoing governance risks, and despite recent rating upgrades, market confidence in its future remains fragile.
See More
Pomerantz LLP Investigates Braskem Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud and other unlawful business practices by Braskem S.A., urging investors to contact attorneys to join the class action, highlighting serious concerns over corporate governance and transparency.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure, but this news led to a 14.71% drop in its ADR price, reflecting market worries about the company's financial health.
- Deteriorating Financial Performance: On March 26, 2026, Braskem reported widening losses and issued a going-concern warning for 2025, causing its ADR price to fall by 10.66%, indicating significant financial pressure on the company.
- Increased Legal Risks: As Pomerantz LLP's investigation progresses, Braskem faces heightened legal risks that could impact its future financing capabilities and market trust, exacerbating investor anxiety.
See More
Braskem Faces Securities Fraud Investigation by Pomerantz LLP
- Investigation Launched: Pomerantz LLP is investigating whether Braskem and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure; however, this news caused its ADR price to drop by 14.71%, reflecting market concerns about its financial health.
- Widening Financial Losses: On March 26, 2026, Braskem reported its fourth quarter and full year 2025 financial results, revealing widening losses and a going-concern warning, which led to a further 10.66% decline in ADR price, indicating the financial pressures the company is facing.
- Potential Legal Consequences: As the investigation unfolds, if Braskem and its executives are found to have engaged in misconduct, it could trigger class action lawsuits, further impacting the company's reputation and shareholder confidence.
See More
Braskem Unveils Sustainable Packaging Solutions at Interpack 2026
- Sustainable Material Innovation: At Interpack 2026, Braskem showcases I'm green™ bio-based polyethylene specifically designed for food-contact applications, marking the first sustainable sugarcane-derived plastics offered, aimed at meeting the growing demand for eco-friendly packaging and facilitating the transition to a low-carbon economy.
- New Healthcare Product: The newly introduced Medcol V7040 low-density polyethylene is specifically developed for the healthcare sector, meeting stringent pharmaceutical regulations while offering excellent flowability and temperature resistance, serving as a true drop-in solution to support sustainable medical packaging.
- Support for Circular Economy: Braskem's portfolio spans renewable to recycled materials, providing multiple solutions that enable brands to achieve sustainability goals while ensuring performance and supply reliability, thus promoting the realization of a circular plastic economy.
- Interactive Exhibition Highlights: At Interpack, Braskem will feature interactive displays and expert sessions to highlight its product innovations in the circular plastic economy, emphasizing their potential applications across food, healthcare, and personal care sectors.
See More
Braskem to Transfer Control to Shine I Fund
- Control Transfer Agreement: Braskem announced that Novonor and NSP Investimentos have signed an agreement to sell control of the company to private equity fund Shine I, managed by IG4 Capital, with completion expected within 30 days, indicating a significant shift in governance structure.
- Shareholders Agreement Upcoming: Within the next 30 days, Shine I and Petrobras are expected to sign a new shareholders' agreement governing Braskem's operations, further solidifying the new investor's control over the company.
- Petrobras Evaluation: Petrobras, which currently owns 47% of Braskem's voting shares and 36.1% of its total shares, is evaluating the terms of the transaction to decide on its waiver rights, which could impact the final outcome of the deal.
- Voting Shares Sale Details: The agreement details the court-supervised sale of approximately 50.1% of Braskem's voting shares and about 34.3% of its total shares, reflecting a significant adjustment in the shareholder structure that may influence future operational strategies and market performance.
See More
Braskem Faces Securities Fraud Investigation by Pomerantz LLP
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Braskem and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Capital Structure Optimization: On September 26, 2025, Braskem announced it had retained financial and legal advisors to optimize its capital structure; however, this news caused its ADR price to drop by 14.71%, indicating market concerns about its financial health.
- Deteriorating Financial Performance: On March 26, 2026, Braskem reported widening losses and issued a going-concern warning in its 2025 financial results, further undermining investor confidence.
- ADR Price Volatility: Following the financial report, Braskem's ADR price fell by 10.66% to $3.52 per ADR, reflecting a pessimistic outlook from the market regarding its future prospects.
See More
Braskem Reports Q4 Losses Nearly Doubling, Faces Material Uncertainty
- Deteriorating Financials: Braskem reported a Q4 net loss of 10.28 billion reais (approximately $1.96 billion), nearly doubling from 5.64 billion reais a year earlier, indicating significant challenges in financial management that could impact future financing capabilities.
- Revenue Decline: The company's Q4 net revenue fell by 7% to 16.1 billion reais, primarily due to tax writedowns, provisions related to the Alagoas salt mine incident, and currency effects, suggesting that while the core business remains intact, external factors have significantly pressured performance.
- Rising Debt: Braskem's adjusted net debt increased to $7.5 billion in Q4, with leverage surging to 14.74x, reflecting severe risks to its debt repayment capacity, potentially forcing the company to seek bankruptcy protection or pursue out-of-court restructuring in the coming months.
- Ongoing Governance Risks: Following multiple failed divestment attempts by controlling shareholder Novonor after Brazil's Carwash corruption scandal, Braskem faces ongoing governance risks, and despite recent rating upgrades, market confidence in its future remains fragile.
See More
